Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature

Glucagon-like peptide one-receptor agonists (GLP-1 RA) are drugs that differ in their pharmacological composition and homology to human GLP-1 and are used most frequently for the treatment of type 2 diabetes and weight loss. There are isolated reports of eosinophilic adverse reactions associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Posso-Osorio, Iván, Vargas-Potes, Carlos Julio, Mejía, Mauricio, Cañas, Carlos A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Case Based Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412476/
https://www.ncbi.nlm.nih.gov/pubmed/37199890
http://dx.doi.org/10.1007/s10067-023-06612-w
_version_ 1785086914508881920
author Posso-Osorio, Iván
Vargas-Potes, Carlos Julio
Mejía, Mauricio
Cañas, Carlos A.
author_facet Posso-Osorio, Iván
Vargas-Potes, Carlos Julio
Mejía, Mauricio
Cañas, Carlos A.
author_sort Posso-Osorio, Iván
collection PubMed
description Glucagon-like peptide one-receptor agonists (GLP-1 RA) are drugs that differ in their pharmacological composition and homology to human GLP-1 and are used most frequently for the treatment of type 2 diabetes and weight loss. There are isolated reports of eosinophilic adverse reactions associated with GLP-1 RA. We present the case of a 42-year-old female patient who, after starting weekly subcutaneous semaglutide, developed eosinophilic fasciitis with favorable clinical evolution after the discontinuation of semaglutide and the initiation of immunosuppression. A review of the eosinophilic adverse events that have been previously reported with GLP-1 RA is provided.
format Online
Article
Text
id pubmed-10412476
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-104124762023-08-11 Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature Posso-Osorio, Iván Vargas-Potes, Carlos Julio Mejía, Mauricio Cañas, Carlos A. Clin Rheumatol Case Based Review Glucagon-like peptide one-receptor agonists (GLP-1 RA) are drugs that differ in their pharmacological composition and homology to human GLP-1 and are used most frequently for the treatment of type 2 diabetes and weight loss. There are isolated reports of eosinophilic adverse reactions associated with GLP-1 RA. We present the case of a 42-year-old female patient who, after starting weekly subcutaneous semaglutide, developed eosinophilic fasciitis with favorable clinical evolution after the discontinuation of semaglutide and the initiation of immunosuppression. A review of the eosinophilic adverse events that have been previously reported with GLP-1 RA is provided. Springer International Publishing 2023-05-18 2023 /pmc/articles/PMC10412476/ /pubmed/37199890 http://dx.doi.org/10.1007/s10067-023-06612-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Case Based Review
Posso-Osorio, Iván
Vargas-Potes, Carlos Julio
Mejía, Mauricio
Cañas, Carlos A.
Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature
title Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature
title_full Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature
title_fullStr Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature
title_full_unstemmed Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature
title_short Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature
title_sort eosinophil-related diseases during treatment with glucagon-like peptide one receptor (glp-1 ra): a case report and review of the literature
topic Case Based Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412476/
https://www.ncbi.nlm.nih.gov/pubmed/37199890
http://dx.doi.org/10.1007/s10067-023-06612-w
work_keys_str_mv AT possoosorioivan eosinophilrelateddiseasesduringtreatmentwithglucagonlikepeptideonereceptorglp1raacasereportandreviewoftheliterature
AT vargaspotescarlosjulio eosinophilrelateddiseasesduringtreatmentwithglucagonlikepeptideonereceptorglp1raacasereportandreviewoftheliterature
AT mejiamauricio eosinophilrelateddiseasesduringtreatmentwithglucagonlikepeptideonereceptorglp1raacasereportandreviewoftheliterature
AT canascarlosa eosinophilrelateddiseasesduringtreatmentwithglucagonlikepeptideonereceptorglp1raacasereportandreviewoftheliterature

Ejemplares similares